<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02748876</url>
  </required_header>
  <id_info>
    <org_study_id>113</org_study_id>
    <nct_id>NCT02748876</nct_id>
  </id_info>
  <brief_title>Effect of His-Ventricular (HV) Interval Optimisation in Cardiac Resynchronisation Therapy</brief_title>
  <official_title>A Randomised Cross-over Pilot Study of the Effect of His-Ventricular (HV) Interval Optimisation in Cardiac Resynchronisation Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hull University Teaching Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hull University Teaching Hospitals NHS Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiac resynchronisation therapy (CRT) is a specialised type of pacemaker used in patients&#xD;
      with severe heart failure to improve symptoms and survival. Approximately one third of&#xD;
      patients treated with CRT do not notice significant improvement in their symptoms and this&#xD;
      may be due to inadequate co-ordination between the upper and lower chambers of the heart&#xD;
      (atrioventricular dyssynchrony).&#xD;
&#xD;
      The investigators propose a new method to achieve atrioventricular synchrony in CRT based on&#xD;
      measurements of electrical conduction from within the heart. Patients referred for CRT&#xD;
      implantation at Castle Hill Hospital are eligible to participate. During CRT implantation,&#xD;
      additional measurements, will be recorded from within the heart. After implantation, device&#xD;
      settings will be adjusted to either standard or electrophysiologically-optimised settings&#xD;
      with cross-over at 4 months.&#xD;
&#xD;
      The investigators hypothesis is that patients with optimised settings will derive additional&#xD;
      benefit compared to patients with standard pacemaker-determined settings.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 29, 2016</start_date>
  <completion_date type="Actual">March 15, 2018</completion_date>
  <primary_completion_date type="Actual">April 28, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in amino-terminal pro-B-type natriuretic peptide (NT-proBNP)</measure>
    <time_frame>7 months and 11 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Increase in 6-min walk test distance by ≥25 m</measure>
    <time_frame>7 months and 11 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>≥5points improvement in the short Kansas City Cardiomyopathy Questionnaire score</measure>
    <time_frame>7 months and 11 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of left ventricular end-diastolic volume.</measure>
    <time_frame>7 months and 11 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>His-Ventricular (HV)-optimised</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>His-Ventricular (HV) optimised atrioventricular delay</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-optimised</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard atrioventricular delay</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>His-Ventricular (HV) optimisation</intervention_name>
    <description>Optimisation of atrioventricular pacing interval</description>
    <arm_group_label>His-Ventricular (HV)-optimised</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of heart failure&#xD;
&#xD;
          -  Referred for cardiac resynchronisation therapy (CRT) with or without defibrillator&#xD;
&#xD;
          -  In sinus rhythm&#xD;
&#xD;
          -  Patients must have a telephone&#xD;
&#xD;
          -  Ability to give informed consent&#xD;
&#xD;
          -  Ability to complete the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe valve disease or previous valve replacement&#xD;
&#xD;
          -  Previous atrial flutter ablation&#xD;
&#xD;
          -  Chronic kidney disease Stage 3 or above&#xD;
&#xD;
          -  Recent myocardial infarction&#xD;
&#xD;
          -  Ongoing cardiac ischaemia&#xD;
&#xD;
          -  Infiltrative cardiomyopathy&#xD;
&#xD;
          -  Wolff-Parkinson White syndrome&#xD;
&#xD;
          -  Presence of second or third degree heart block&#xD;
&#xD;
          -  &lt;90% biventricular pacing at 3 months&#xD;
&#xD;
          -  Hypertrophic cardiomyopathy&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  On treatment for hypothyroidism or hyperthyroidism&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Castle Hill Hospital</name>
      <address>
        <city>Hull</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>April 20, 2016</study_first_submitted>
  <study_first_submitted_qc>April 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2016</study_first_posted>
  <last_update_submitted>July 15, 2019</last_update_submitted>
  <last_update_submitted_qc>July 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

